← Nippon India Mutual Fund
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High RiskISIN INF204K01I50
NAV · 06-Jul-2026
₹634.5567
1M
+6.46%
6M
+10.62%
1Y (CAGR)
+9.51%
3Y (CAGR)
+22.47%
5Y (CAGR)
+13.74%
Since inception (CAGR)
+17.75%
NAV history
hover for values
Risk & SIP analytics
Q1 · TOP · 3Y in categoryVolatility (3y)
13.03%
Downside dev (3y)
9.10%
Max drawdown (3y)
-14.7%
Sharpe (3y)
1.23
SIP XIRR (3y)
+14.88%
SIP XIRR (5y)
+18.27%
Calendar-year returns
2020 +67.9%2021 +25.1%2022 -9.1%2023 +40.4%2024 +35.3%2025 -2.5%
Fund facts
Fund managerSailesh Raj Bhan · Kinjal Desai · Amber Singhania
AUM₹86,357 Cr
Expense ratio0.79% · 2026-05-31
TER · AMFI officialDirect 1.02% · Regular 1.86% (2026-06-30)
Launch date10-May-2004
Plan typeOpen Ended · Equity
Min lumpsum₹5,000
Min SIP₹100
Lock-inNone
Volatility15.44
AMCNippon Life India Asset Management Limited
Objective · The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
scheme documents ↗